Exelixis
As of the edition of 20 October 2026, Exelixis runs 20 drugs, 1 of them marketed; it is on route A at 34 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 5 |
| Went quiet | 4 |
| Stopped | 9 |
| Status not established | 1 |
| Total | 20 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Cabozantinib | Ends 2032 (exclusivity) | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 34 targets, route B at 1 target.
All 35 rows on route A or B
In the product35 company-target rows on route A or B; 32 are not shown here, and no score is.
See all 35 targets where Exelixis needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 50 trials led
- Urinary and reproductive: 17 trials led
- Digestive system: 15 trials led